Mode
Text Size
Log in / Sign up
Phase 3 N=2,222 Randomized Quadruple-blind Treatment

Oral Sulopenem Versus Amoxicillin/Clavulanate for Uncomplicated Urinary Tract Infection in Adult Women

Urinary Tract Infections · Cystitis

Enrolled (actual)
2,222
Serious AEs
0.2%
Results posted
Nov 2024
Primary outcome: Primary: Overall Success — 318; 260 Participants

Study Design & Population

Study type
Interventional
Phase
Phase 3
Interventions
Sulopenem etzadroxil/probenecid (Drug); Amoxicillin/clavulanate (Drug)
Age
Adult, Older Adult · 18+ yrs
Sex
Female
Sponsor
Iterum Therapeutics, International Limited
Primary completion
Nov 2023

Outcome Measures

OutcomeResultp-value
PRIMARY
Overall Success
318; 260
PRIMARY
Overall Success Susceptible Population
296; 243
SECONDARY
Clinical Success Modified Intent-to-treat Population
851; 849
SECONDARY
Clinical Success
397; 358
SECONDARY
Clinical Success Susceptible Population
371; 339
SECONDARY
Microbiologic Success
390; 315
SECONDARY
Microbiologic Success Susceptible Population
361; 295

Summary

Study 310 is a clinical study which compares the effectiveness of oral sulopenem versus oral amoxicillin/clavulanate for the treatment of adult women with uncomplicated urinary tract infection.

Eligibility Criteria

Inclusion Criteria

  • Female patients ≥18 years of age with ≥24 hours and ≤96 hours of urinary symptoms attributable to a UTI
  • Two of the following signs and symptoms of uUTI: urinary frequency, urinary urgency, pain or burning on micturition, suprapubic pain.
  • A mid-stream urine specimen with evidence of pyuria as defined by either a machine-read dipstick positive for leukocyte esterase OR at least 10 white blood cells per cubic millimeter on microscopic analysis of unspun urine OR white blood cell count ≥10 cells/high-powered field (HPF) in the sediment of a spun urine

Exclusion Criteria

  • Presence of signs and symptoms suggestive of acute pyelonephritis defined as: fever (temperature > 38° Celsius), chills, costovertebral angle tenderness, flank pain, nausea, and/or vomiting
  • Receipt of antibacterial drug therapy potentially effective as treatment of uUTI within the prior 7 days
  • Concurrent use of non-study treatments that would have a potential effect on outcome evaluations in patients with uUTI, including analgesics (e.g., non-steroidal anti-inflammatory drugs, aspirin, paracetamol etc.), phenazopyridine, and cranberry products.
  • Any anatomical abnormality of the urinary tract, including surgically modified urinary tract anatomy, and obstructive uropathy due to nephrolithiasis, stricture, tumor, or fibrosis
  • Ongoing urinary retention
  • Neurogenic bladder
  • Current resident of a long-term care facility
  • Instrumentation of urinary tract in the previous 30 days
  • An indwelling urinary catheter, ureteral stent or other foreign material in the urinary tract
  • Any history of trauma to the pelvis or urinary tract
  • Receiving hemodialysis, hemofiltration, peritoneal dialysis, or had a renal transplant
  • History of allergy or hypersensitivity to carbapenems, β-lactams or probenecid, as formulated with their excipients
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT05584657). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search